Development of poly(butylene succinate) microspheres for delivery of levodopa in the treatment of Parkinson's disease

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 101 B, Issue 5, 2013, Pages 840-847

  Mohanraj, Krithika ^a   Sethuraman, Swaminathan ^a   Krishnan, Uma Maheswari ^a  

^a SASTRA UNIVERSITY   (India)

Author keywords

levodopa; Parkinson's; poly(butylene succinate); porous; simulated CSF; smooth

Indexed keywords

LEVODOPA; PARKINSON'S; POLY (BUTYLENE SUCCINATE); POROUS; SIMULATED CSF; SMOOTH;

BIOCHEMISTRY; BUTENES; DRUG DELIVERY; EMULSIFICATION; ENCAPSULATION; METAL IONS; MICROSPHERES; NEURODEGENERATIVE DISEASES; NEURONS;

DRUG PRODUCTS;

LEVODOPA; MICROSPHERE; POLY(BUTYLENE SUCCINATE); POLYMER; TRANSFERRIN; UNCLASSIFIED DRUG; ANTIPARKINSON AGENT; BIOMATERIAL; BIONOLE; BUTANEDIOL; SOLVENT; SURFACTANT; DELAYED RELEASE FORMULATION; PHOSPHATE BUFFERED SALINE; SODIUM ION;

ARTICLE; BLOOD BRAIN BARRIER; DRUG CONJUGATION; DRUG DECOMPOSITION; DRUG DELIVERY SYSTEM; DRUG STABILITY; DRUG STRUCTURE; EMULSION; ENCAPSULATION; EVAPORATION; IN VITRO STUDY; PARKINSON DISEASE; PH; PHASE SEPARATION; PHASE TRANSITION; SURFACE PROPERTY; SURFACE TENSION; SUSTAINED DRUG RELEASE; TEMPERATURE; THERMOSTABILITY; BIOAVAILABILITY; CEREBROSPINAL FLUID; CHEMISTRY; DELAYED RELEASE FORMULATION; HUMAN; MATERIALS TESTING; POROSITY; SCANNING ELECTRON MICROSCOPY; DRUG BIOAVAILABILITY; MICROEMULSION; MICROENCAPSULATION;

ANTIPARKINSON AGENTS; BIOCOMPATIBLE MATERIALS; BIOLOGICAL AVAILABILITY; BLOOD-BRAIN BARRIER; BUTYLENE GLYCOLS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; LEVODOPA; MATERIALS TESTING; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; PARKINSON DISEASE; POLYMERS; POROSITY; SOLVENTS; SURFACE PROPERTIES; SURFACE-ACTIVE AGENTS;

EID: 84878859974     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.32888     Document Type: Article

References (30)

1. DeLong MR, Juncos JL,. Harrison's Principle of Internal Medicine, 17th ed. Mc Graw-Hill; 2008. p. 2549-2559: Newyork.
2. Ngwuluka N, Pillay V, Du Toit LC, Ndesendo V, Choonara Y, Modi G, Naidoo D,. Levodopa delivery systems: Advancements in delivery of the gold standard. Expert Opin Drug Deliv 2010; 7: 203-224.
3. Jankovic JJ, Tolosa E,. Parkinson's disease and movement disorders, 4th ed. Lippincott Williams and Wilkins; 2002: p. 90-114: Philadelphia, USA.
4. Arica B, Kas HS, Moghdam A, Akalan N, Hincal AA,. Carbidopa/levodopa- loaded biodegradable microspheres: In vivo evaluation on experimental Parkinsonism in rats. J Control Release 2005; 102: 689-697.
5. Bennewitz MF, Saltzman M,. Nanotechnology for delivery of drugs to the brain for epilepsy. Neurotherapeutics 2009; 6: 323-336.
6. Pathan SA, Iqbal Z, Zaidi SMA, Talgaonkar S, Vohra D, Jain GK, Azeem A, Jain N, Lalani JR, Khar RK, Ahmad FJ,. CNS drug delivery systems: Novel approaches. RecentPat Drug Deliv Formul 2009; 3: 71-89.
7. Degueurce AM, Hjorth S, Manson DW, Dillon DL, Tice TR,. Implantable microencapsulated dopamine (DA): A new approach for slow-release DA delivery into brain tissue. Neurosci Lett 1988; 92: 303-309.
8. Schroeder U, Sommerfeld P, Ulrich S, Sabel BA,. Naonoparticle technology for delivery of drugs across the blood brain barrier. J Pharm Sci 1998; 87: 1305-1307.
9. Fillebeen C, Descamps L, Dehoucks MP, Fenart L, Benaissa M, Spik G, Cecchelli R, Pierce A,. Receptor-mediated transcytosis of lactoferrin through the blood brain barrier. J Biol Chem 1999; 274: 7011-7017.
10. Chang J, Jallouli Y, Kroubi M, Yuan XB, Feng W, Kang CS, Pu PV, Betbeder D,. Characterization of endocytosis of transferrin coated PLGA nanoparticles by the blood brain barrier. Int J Pharm 2009; 379: 285-292.
11. Gunatillake PA, Adhikari R,. Biodegradable synthetic polymers for tissue engineering. Eur Cells Mater 2003; 5: 1-16.
12. Ikada Y, Tsuji H,. Biodegradable polyesters for medical and ecological applications. Macromol Rapid Comm 2000; 21: 117-132.
13. Sethuraman S, Nair LS, El-Amin S, Nguyen MT, Singh A, Krogman N, Greish YE, Allcock HR, Brown PW, Laurencin CT,. Mechanical properties and osteocompatibility of novel biodegradable alanine based polyphosphazenes: Side group effects. Acta Biomater 2010; 6: 1931-1937.
14. Subramanian A, Krishnan UM, Sethuraman S,. Fabrication of uniaxially aligned 3D electrospun scaffolds for neural regeneration. Biomed Mater 2011; 6: 1-10
15. Han Y, Kim S, Kim J,. Preparation and characterization of high molecular weight poly(butylene succinate). Macromol Res 2002; 10: 108-114.
16. 2 based on the ISO 14855-2 Method. Int J Mol Sci 2009; 10: 4267-4283.
17. Burgen ASV, Chipman LM,. Cholinesterase and succinic dehydrogenase in the central nervous system of the dog. J Physiol 1951; 114: 296-305.
18. Mandhane SN, Khisti RT, Chopde CT,. Adenosinergic modulation of 3α-hydroxy-5α-pregnan-20-one induced catalepsy in mice. Psychopharmacology 1999; 144: 398-404.
19. Zhang Q, Liu J, Wang X, Li M, Yang J,. Controlling internal nanostructures of porous microspheres prepared via electrospraying. Colloid Polym Sci 2010; 288: 1385-1391.
20. Barrow MS, Jones RL, Park JO, Wright CJ, Williams PR, Srinivasarao M,. Studies of the formation of microporous polymer films in breath figure condensation processes. Mod Phys Lett B 2008; 22: 1989-1996.
21. Srinivasarao M, Collings D, Philips A, Patel S,. Three-dimensionally ordered array of air bubbles in a polymer film. Science 2001; 292: 79-83.
22. Yang C, Plackett D, Needham D, Brut HM,. PLGA and PHBV microsphere formulations and solid-state characterization: Possible implications for local delivery of fusidic acid for the treatment and prevention of orthopaedic infections. Pharm Res 2009; 26: 1644-1656.
23. Hua FJ, Park TG, Lee DS,. A facile preparation of highly interconnected macroporous PLGA scaffolds by liq-liq phase separation of a PLGA-dioxane-water ternary system. Polymer 2003; 44: 1911-1920.
24. Pérez MH, Zinutti C, Lamprecht A, Ubrich N, Astier A, Hoffman M, Bodmeier R, Maincent P,. The preparation and evaluation of poly(epsilon- caprolactone) microparticles containing both a lipophilic and a hydrophilic drug. J Control Release 2000; 65: 429-438.
25. Freiberg S, Zhu XX,. Polymer microspheres for controlled drug release. Int J Pharm 2004; 282: 1-18.
26. Silverstein RM, Bassler GC, Morrill TC,. Spectrometric identification of organic compounds, 4th ed. John Wiley and Sons; 1981: p. S6.
27. Cho SH, Ryu JH, Park JG, Suh KD,. Surface modification of monodisperse hydroxyl functionalized polymeric microspheres using ceric ammonium nitrate. Eur Polym J 2005; 41: 2209-2215.
28. Yeo Y, Park K,. Control of encapsulation efficiency and initial burst in polymeric microparticle systems. Arch Pharm Res 2004; 27: 1-12.
29. Robson HJ, Craig DQM, Deutsch D,. An investigation into the release of cefuroxime axetil from taste-masked stearic acid microspheres: Part 1: The influence of the dissolution medium on the drug release profile and the physical integrity of the microspheres. Int J Pharm 1999; 190: 183-192.
30. Robson HJ, Craig DQM, Deutsch D,. An investigation into the release of cefuroxime axetil from taste-masked stearic acid microspheres, part 11. The effect of buffer composition on drug release. Int J Pharm 2000; 195: 137-145.